FC
VRTX icon

Fulcrum Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Fulcrum Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.37M Sell
16,496
-120
-0.7% -$56K 1.6% 19
2025
Q4 		$7.53M Buy
16,616
+360
+2% +$155K 1.51% 24
2025
Q3 		$6.37M Buy
16,256
+458
+3% +$191K 1.31% 29
2025
Q2 		$7.03M Buy
15,798
+220
+1% +$101K 1.49% 24
2025
Q1 		$7.55M Buy
15,578
+84
+0.5% +$39.1K 1.67% 20
2024
Q4 		$6.24M Buy
15,494
+108
+0.7% +$50.1K 1.31% 26
2024
Q3 		$7.16M Sell
15,386
-10
-0.1% -$4.8K 1.56% 26
2024
Q2 		$7.22M Buy
15,396
+202
+1% +$87.7K 1.64% 24
2024
Q1 		$6.35M Buy
15,194
+123
+0.8% +$52K 1.51% 24
2023
Q4 		$6.13M Sell
15,071
-820
-5% -$303K 1.59% 24
2023
Q3 		$5.53M Sell
15,891
-60
-0.4% -$21K 1.6% 21
2023
Q2 		$5.61M Sell
15,951
-713
-4% -$240K 1.48% 25
2023
Q1 		$5.25M Buy
16,664
+3,033
+22% +$910K 1.41% 29
2022
Q4 		$3.94M Buy
13,631
+10,203
+298% +$3.11M 1.14% 35
2022
Q3 		$993K Sell
3,428
-305
-8% -$87.8K 0.29% 50
2022
Q2 		$1.05M Buy
+3,733
New +$999K 0.33% 44

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fulcrum Capital's VRTX Position: Q1 2026 in Review

Fulcrum Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 0.72% in Q1 2026, selling an estimated $56K and leaving 16,496 shares worth $7.37M. The position accounts for 1.6% of the portfolio, ranked #19.

Fulcrum Capital first reported a position in VRTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $7.55M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Fulcrum Capital held 16,496 shares of Vertex Pharmaceuticals worth $7.37M as of Q1 2026.
  • Fulcrum Capital sold 120 Vertex Pharmaceuticals shares in Q1 2026, an estimated $56K.
  • Vertex Pharmaceuticals made up 1.6% of Fulcrum Capital's portfolio in Q1 2026, its #19 holding.
  • Fulcrum Capital first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • Fulcrum Capital's Vertex Pharmaceuticals position peaked at $7.55M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fulcrum Capital's 13F filing for Q1 2026, filed 30 Apr 2026.